Intangible inventions: the Kalbeliya gypsy dance form, from its creation to UNESCO recognition

Despite the creation of the Kālbeliyā dance form in the 1980s, it was recognized as a UNESCO intangible cultural heritage in 2010. Rajasthani “Gypsy” performances,featuring a dance designed by the nomadic Kālbeliyā community, have quickly become popular among tourists in India as well as on Western world music stages. The state of Rajasthan, where the Kālbeliyās hail from, is celebrated as “India’s heritage state” by the Indian government as it seeks to promote tourism and the international dissemination of Indian culture through performances and festivals. In this paper, I sketch the history of the Kālbeliyā dance form from its origins in the 1980s through to the UNESCO nomination in 2010. Moreover, I discuss the effects of its recognition as a world heritage dance tradition. The official approval of the Kalbeliya dance form as a heritage activity further highlights the challenges to UNESCO’s candidate selection process. This paper aims to explain the reasons for the nomination of the Kālbeliyā dance form (how and why UNESCO was persuaded to recognize it as a suitable candidate) by connecting this to the continued processes of nationalism and romanticism, the economic strategies adopted by the cultural tourism industry and the commodification and commercialization of Indian folk arts

Pteris vittata L. the correct name for "Pteris longifolia"

Abstract not availabl

Cost-effectiveness thresholds : pros and cons

Cost-effectiveness analysis is used to compare the costs and outcomes of alternative policy options. Each resulting cost-effectiveness ratio represents the magnitude of additional health gained per additional unit of resources spent. Cost-effectiveness thresholds allow cost-effectiveness ratios that represent good or very good value for money to be identified. In 2001, the World Health Organization’s Commission on Macroeconomics in Health suggested cost-effectiveness thresholds based on multiples of a country’s per-capita gross domestic product (GDP). In some contexts, in choosing which health interventions to fund and which not to fund, these thresholds have been used as decision rules. However, experience with the use of such GDP-based thresholds in decision-making processes at country level shows them to lack country specificity and this-in addition to uncertainty in the modelled cost-effectiveness ratios-can lead to the wrong decision on how to spend health-care resources. Cost-effectiveness information should be used alongside other considerations-e.g. budget impact and feasibility considerations-in a transparent decision-making process, rather than in isolation based on a single threshold value. Although cost-effectiveness ratios are undoubtedly informative in assessing value for money, countries should be encouraged to develop a context-specific process for decision-making that is supported by legislation, has stakeholder buy-in, for example the involvement of civil society organizations and patient groups, and is transparent, consistent and fair

Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries

Abstract Objective: To identify pharmaceutical policy changes during the economic recession in eight European countries and to determine whether policy measures resulted in lower sales of, and less expenditure on, pharmaceuticals. Methods: Information on pharmaceutical policy changes between 2008 and 2011 in eight European countries was obtained from publications and pharmaceutical policy databases. Data on the volume and value of the quarterly sales of products between 2006 and 2011 in the 10 highest-selling therapeutic classes in each country were obtained from a pharmaceutical market research database. We compared these indicators in economically stable countries; Austria, Estonia and Finland, to those in economically less stable countries, Greece, Ireland, Portugal, Slovakia and Spain. Findings: Economically stable countries implemented two to seven policy changes each, whereas less stable countries implemented 10 to 22 each. Of the 88 policy changes identified, 33 occurred in 2010 and 40 in 2011. They involved changing out-of-pocket payments for patients in 16 cases, price mark-up schemes in 13 and price cuts in 11. Sales volumes increased moderately in all countries except Greece and Portugal, which experienced slight declines after 2009. Sales values decreased in both groups of countries, but fell more in less stable countries. Conclusion: Less economically stable countries implemented more pharmaceutical policy changes during the recession than economically stable countries. Unexpectedly, pharmaceutical sales volumes increased in almost all countries, whereas sales values declined, especially in less stable countries

Guiding Service Composition in a Visual Service Creation Environment

Current day service composition languages like WS-BPEL require in-depth knowledge of this language by the service composition designers. In this paper we present a high-level, visual Service Creation Environment (SCE). This SCE provides service composition templates, verifica-tion of compatibility and guidelines, and advanced separa-tion of concerns through Aspect-Oriented Software Devel-opment. Composition templates are abstract descriptions of reusable compositions containing several placeholders for services. Services are verified to be compatible with the composition template when a service is mapped onto a composition template’s placeholder. Composition guide-lines such as QoS constraints can be added to the SCE and verified. The modularization of crosscutting concerns is supported by the SCE through the general-purpose Padus Aspect-Oriented Programming language and the possibil-ity to add concern-specific languages on top of Padus. The SCE generates the appropriate WS-BPEL processes given a complete and verified service composition. 1

The economic pressures for biosimilar drug use in cancer medicine

The main rationale for using biosimilar drugs is for cost saving. The market development for biosimilar drugs will therefore depend on the degree to which cost saving measures are required by nations, medical insurers and individuals and the absolute savings that could be gained by switching from original drugs. This paper is designed to discover the degree to which financial constraints will drive future health spending and to discover if legal or safety issues could impact on any trend. A structured literature search was performed for papers and documents to 27 August 2011. Where multiple sources of data were available on a topic, data from papers and reports by multinational or national bodies were used in preference to data from regions or individual hospitals. Almost all health systems face current significant cost pressures. The twin driver of increasing cancer prevalence as populations age and cancer medicine costs rising faster than inflation places oncology as the most significant single cost problem. For some countries, this is predicted to make medicine unaffordable within a decade. Most developed countries have planned to embrace biosimilar use as a cost-control measure. Biosimilar introduction into the EU has already forced prices down, both the price of biosimilar drugs and competitive price reductions in originator drugs. Compound annual growth rates of use have been predicted at 65.8% per year. Most developed countries have planned to embrace biosimilar use as a major cost-control measure. Only legal blocks and safety concerns are likely to act against this trend. For centralised healthcare systems, and those with a strong tradition of generic medicine use, biosimilar use will clearly rise with predictions of more than 80% of prescriptions of some biologic drugs within 1 year of market entry in the USA. Delaying the implementation of such programmes however risks a real crisis in healthcare delivery for many countries and hospitals that few can now afford